175 related articles for article (PubMed ID: 17344303)
41. Quantifying the Sensitivity of HIV-1 Viral Entry to Receptor and Coreceptor Expression.
Mistry B; D'Orsogna MR; Webb NE; Lee B; Chou T
J Phys Chem B; 2016 Jul; 120(26):6189-99. PubMed ID: 27137677
[TBL] [Abstract][Full Text] [Related]
42. HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes.
García-Expósito L; Barroso-González J; Puigdomènech I; Machado JD; Blanco J; Valenzuela-Fernández A
Mol Biol Cell; 2011 Apr; 22(8):1148-66. PubMed ID: 21346189
[TBL] [Abstract][Full Text] [Related]
43. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.
Goffinet C; Allespach I; Keppler OT
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):1015-20. PubMed ID: 17209012
[TBL] [Abstract][Full Text] [Related]
44. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
45. Himalayan bioactive molecules as potential entry inhibitors for the human immunodeficiency virus.
Kumar Bhardwaj V; Purohit R; Kumar S
Food Chem; 2021 Jun; 347():128932. PubMed ID: 33465692
[TBL] [Abstract][Full Text] [Related]
46. Chemically induced infection of CD4-negative HeLa cells with HIV-1.
Harada S; Maeda Y
Microbiol Immunol; 1999; 43(12):1077-86. PubMed ID: 10656175
[TBL] [Abstract][Full Text] [Related]
47. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection.
Mañes S; del Real G; Lacalle RA; Lucas P; Gómez-Moutón C; Sánchez-Palomino S; Delgado R; Alcamí J; Mira E; Martínez-A C
EMBO Rep; 2000 Aug; 1(2):190-6. PubMed ID: 11265761
[TBL] [Abstract][Full Text] [Related]
48. Neutrophils Turn Plasma Proteins into Weapons against HIV-1.
Speth C; Brodde MF; Hagleitner M; Rambach G; Van Aken H; Dierich M; Kehrel BE
PLoS One; 2013; 8(6):e66073. PubMed ID: 23840401
[TBL] [Abstract][Full Text] [Related]
49. Potent suppression of HIV-1 cell attachment by Kudzu root extract.
Mediouni S; Jablonski JA; Tsuda S; Richard A; Kessing C; Andrade MV; Biswas A; Even Y; Tellinghuisen T; Choe H; Cameron M; Stevenson M; Valente ST
Retrovirology; 2018 Sep; 15(1):64. PubMed ID: 30236131
[TBL] [Abstract][Full Text] [Related]
50. Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.
Wensel D; Sun Y; Li Z; Zhang S; Picarillo C; McDonagh T; Fabrizio D; Cockett M; Krystal M; Davis J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584151
[TBL] [Abstract][Full Text] [Related]
51. Blocking HIV-1 entry by a gp120 surface binding inhibitor.
Tsou LK; Chen CH; Dutschman GE; Cheng YC; Hamilton AD
Bioorg Med Chem Lett; 2012 May; 22(9):3358-61. PubMed ID: 22487177
[TBL] [Abstract][Full Text] [Related]
52. Macropinocytosis-like HIV-1 internalization in macrophages is CCR5 dependent and leads to efficient but delayed degradation in endosomal compartments.
Gobeil LA; Lodge R; Tremblay MJ
J Virol; 2013 Jan; 87(2):735-45. PubMed ID: 23115275
[TBL] [Abstract][Full Text] [Related]
53. Gold nanoparticles as an HIV entry inhibitor.
Vijayakumar S; Ganesan S
Curr HIV Res; 2012 Dec; 10(8):643-6. PubMed ID: 22954307
[TBL] [Abstract][Full Text] [Related]
54. CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach.
Baker AM; Saulière A; Gaibelet G; Lagane B; Mazères S; Fourage M; Bachelerie F; Salomé L; Lopez A; Dumas F
J Biol Chem; 2007 Nov; 282(48):35163-8. PubMed ID: 17855336
[TBL] [Abstract][Full Text] [Related]
55. Thioredoxin (Trx1) regulates CD4 membrane domain localization and is required for efficient CD4-dependent HIV-1 entry.
Moolla N; Killick M; Papathanasopoulos M; Capovilla A
Biochim Biophys Acta; 2016 Sep; 1860(9):1854-63. PubMed ID: 27233453
[TBL] [Abstract][Full Text] [Related]
56. Characterizing the anti-HIV activity of papuamide A.
Andjelic CD; Planelles V; Barrows LR
Mar Drugs; 2008; 6(4):528-49. PubMed ID: 19172193
[TBL] [Abstract][Full Text] [Related]
57. The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.
Fleta-Soriano E; Smutná K; Martínez JP; Lorca Oró C; Sadiq SK; Mirambeau G; Lopez-Iglesias C; Bosch M; Pol A; Brönstrup M; Diez J; Meyerhans A
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533249
[TBL] [Abstract][Full Text] [Related]
58. HIV-1 Fusion with CD4+ T cells Is Promoted by Proteins Involved in Endocytosis and Intracellular Membrane Trafficking.
Marin M; Kushnareva Y; Mason CS; Chanda SK; Melikyan GB
Viruses; 2019 Jan; 11(2):. PubMed ID: 30691001
[TBL] [Abstract][Full Text] [Related]
59. Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.
Latinovic OS; Medina-Moreno S; Schneider K; Gohain N; Zapata J; Pazgier M; Reitz M; Bryant J; Redfield RR
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):178-86. PubMed ID: 26059995
[TBL] [Abstract][Full Text] [Related]
60. Linking genotype to phenotype on beads: high throughput selection of peptides with biological function.
Huang LC; Pan X; Yang H; Wan LK; Stewart-Jones G; Dorrell L; Ogg G
Sci Rep; 2013 Oct; 3():3030. PubMed ID: 24149829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
